Almac launches XCEL array
Enables biomarkers within multiple disease areas to be identified
Almac Diagnostics has introduced a proprietary XCEL high-density transcriptome microarray based on the industry standard Affymetrix GeneChip platform.
The Northern Ireland-based company says the content of XCEL has been derived from high quality proprietary sequence data, as well as mining public gene expression and sequence databases. The design methodologies of the array are from validated methods derived from Almac’s range of cancer DSA (Disease Specific Arrays).
XCEL contains 92,000 transcripts, which is said to be significantly more than on any other platform, and the technology is optimised for use with Formalin Fixed Paraffin Embedded (FFPE) tissue.
The company says the substantial content on the XCEL array ensures that the platform technology is suitable for research in cross-disease areas.
‘Our XCEL array provides an ideal platform for the discovery of biomarkers in a range of diseases and where cross-disease compatibility is important. This array becomes an important part of our solutions for the delivery of personalised medicine,’ said Professor Paul Harkin, president and managing director of Almac Diagnostics.
The XCEL array adds to Almac’s portfolio of proprietary discovery arrays, which include Breast DSA, Colorectal DSA, Lung Cancer DSA, Ovarian Cancer DSA and Prostate Cancer DSA.
